Cargando…
Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer
AIMS: Use of the anti‐tumour antibiotic actinomycin D is associated with development of hepatotoxicity, particularly in young children. A paucity of actinomycin D pharmacokinetic data make it challenging to develop a sound rationale for defining dosing regimens in younger patients. The study aim was...
Autores principales: | Walsh, Christopher, Bonner, Jennifer J., Johnson, Trevor N., Neuhoff, Sibylle, Ghazaly, Essam A., Gribben, John G., Boddy, Alan V., Veal, Gareth J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834588/ https://www.ncbi.nlm.nih.gov/pubmed/26727248 http://dx.doi.org/10.1111/bcp.12878 |
Ejemplares similares
-
Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer
por: Hill, Christopher R., et al.
Publicado: (2014) -
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo
por: Hill, Christopher R., et al.
Publicado: (2013) -
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016) -
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study
por: Beghetti, Maurice, et al.
Publicado: (2009) -
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
por: Han, Kelong, et al.
Publicado: (2015)